Choose your location to get a site experience tailored for you.

Remember my region and language settings

Unsere neuesten Erkenntnissen über Biopharmaceuticals

Die Biotech- und Pharmabranche setzt ihre digitale Entwicklung mit hohem Tempo fort, während geopolitische und ökonomische Kräfte Probleme bereiten, die mithilfe einer die gesamte Lieferkette erfassenden und sorgfältig angepassten Strategie gelöst werden müssen. Erkunden Sie die aktuelle Vordenkerrolle von BCG im Bereich Biopharmaceuticals und gewinnen Sie wichtige Erkentnisse über die Zukunft der Life-Sciences-Branche.


Featured Insights

Chasing Value as AI Transforms Health Care

Chasing Value as AI Transforms Health Care

The revolution has come to health care. Artificial intelligence has major repercussions for players across the industry—as well as for new-technology entrants and consumers.

Biopharmaceuticals - Getting a Grip on COGS in Generic Drugs

Getting a Grip on COGS in Generic Drugs

BCG’s 2019 benchmark study found that companies need to relentlessly manage the elements that demand the greatest spending—internal and contract manufacturing.

How US Tax Reform Will Affect Biopharma Supply Chains

Supply chain managers need to ask certain key questions about how the new law will affect their companies’ global networks, investments, and M&A strategies—giving them a better understanding of how to make winning moves.

Biopharmaceuticals in Germany

Placing Your CAR-T Bets

Placing Your CAR-T Bets

These new therapies are poised to revolutionize oncology. It all depends on reaching a larger patient base and simplifying manufacturing and the supply chain.

What is the Right Amount to Spend on Biopharma R&D?

What Is the Right Amount to Spend on Biopharma R&D?

The most successful companies are those with flexible R&D allocation, according to BCG’s Michael Ringel in an article published in Nature Reviews Drug Discovery. These companies actively pursue and invest in the right new scientific opportunities, balance quantitative and qualitative information on scientific feasibility and market need, employ incentives that drive “truth seeking,” and introduce variability into the cost base to enable flexibility in year-to-year investment levels.

Accelerating Drug Development Today

Accelerating Drug Development Today

BCG GAMMA's Transformative Work for an Oncology Center

Using Big Data to Help Fight Cancer

Innovation in Biopharma R&D

Externe Innovationsgrundlagen von einem F&E-Experten

Karalee Close on The Digital Opportunity in Healthcare

Frank Cordes on The Pharma Factory of the Future

Mark Lubkeman on A Return to Growth

protected by reCaptcha

Subscribe to our Biopharma eAlert.

(Bio) Pharma / Pharmaindustrie

SUBSCRIBE

DE